Announcement follows FDA's February 2025 decision to grantradiprodil Breakthrough Therapy designation Company remains on track to initiate Phase 3 pivotal trial ofradiprodil ...

An Atlanta teenager and Clark Atlanta University student is getting a chance to get her life back together after a terrifying ordeal that put her in the hospital. Channel 2’s Linda Stouffer spoke to ...

Christian Chryssos of Monmouth County’s Academy of Allied Health and Science in Neptune will take part in the National Brain ...

Fragile X syndrome is the most common genetically-caused autism spectrum disorder. It causes a range of developmental issues, ...

Members of the American Association for the Advancement of Science have elected Marina Picciotto, Ph.D., Deputy Chair for Basic Science in Psychiatry, Professor of Neuroscience and Pharmacology, and ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

Scientists have created a new therapeutic approach for testing fragile X syndrome, which is the most common genetic cause of ...

MIAMI, FL / / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, tod ...

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New ...

More recently, Bear's lab showed a different dichotomy. It has long been understood from their seminal work in the 1990s that the flow of calcium ions through NMDA receptor can trigger a form of ...